Evidence map›Paper›PMID 39198306›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2024

Proton pencil beam scanning radiotherapy in the postoperative treatment of p16 positive squamous cell tonsillar cancer - evaluation of toxicity and effectivity.

Jiří Kubeš, Sarah Al-Hamami, Silvia Sláviková, Pavel Vítek, Alexandra Haas, Kateřina Dědečková, Barbora Ondrová, Michal Andrlik, Matěj Navrátil, Eliška Rotnáglová and 1 more

Abstract read
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiří KubešProton Therapy Center Czech, Budínova 1a, Prague 8, 18000, Czech Republic.
Sarah Al-HamamiProton Therapy Center Czech, Budínova 1a, Prague 8, 18000, Czech Republic.
Silvia SlávikováProton Therapy Center Czech, Budínova 1a, Prague 8, 18000, Czech Republic.
Pavel VítekProton Therapy Center Czech, Budínova 1a, Prague 8, 18000, Czech Republic.
Alexandra HaasProton Therapy Center Czech, Budínova 1a, Prague 8, 18000, Czech Republic.
Kateřina DědečkováProton Therapy Center Czech, Budínova 1a, Prague 8, 18000, Czech Republic.
Barbora OndrováProton Therapy Center Czech, Budínova 1a, Prague 8, 18000, Czech Republic.
Michal AndrlikProton Therapy Center Czech, Budínova 1a, Prague 8, 18000, Czech Republic. michal.andrlik@ptc.cz.ORCID http://orcid.org/0000-0001-6581-5583
Matěj NavrátilProton Therapy Center Czech, Budínova 1a, Prague 8, 18000, Czech Republic.
Eliška RotnáglováProton Therapy Center Czech, Budínova 1a, Prague 8, 18000, Czech Republic.
Vladimír VondráčekProton Therapy Center Czech, Budínova 1a, Prague 8, 18000, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients with p16 positive tonsillar cancer (p16 + TC) have an excellent prognosis and long-life expectancy. Deintensification of therapy is a prevalent topic of discussion. Proton radiotherapy is one way to reduce radiation exposure and thus reduce acute and late toxicity. The aim is to evaluate treatment outcomes and toxicity of postoperative treatment with intensity-modulated proton therapy (IMPT).

methodsBetween September 2013 and November 2021, 47 patients with p16 + TC were treated postoperatively with IMPT. Median age was 54.9 (38.2-74.9) years, 31 were males and 16 were females. All patients had squamous cell carcinoma and underwent surgery as a primary treatment. Median dose of radiotherapy was 66 GyE in 33 fractions. Bilateral neck irradiation was used in 39 patients and unilateral in 8. Concomitant chemotherapy was applied in 24 patients.

resultsMedian follow-up time was 4.2 (0.15-9.64) years. Five-year overall survival, relapse free survival and local control were 95.7%, 97.8% and 100%. The most common acute toxicities were dermatitis and mucositis, with grade 2 + in 61.7% and 70.2% of patients. No acute percutaneous gastrostomy insertion was necessary and intravenous rehydration was used in 12.8% of patients. The most common late toxicity was grade 1 xerostomia in 70.2% of patients and grade 2 in 10.6% of patients. Subcutaneous fibrosis of grades 2 and 3 occurred in 17.0% and 2.1% of patients, respectively. One patient developed late severe dysphagia and became PEG-dependent.

conclusionIMPT for the postoperative treatment of p16 + TC is feasible with excellent efficiency and acceptable acute and late toxicity.

Indexed as

Carcinoma, Squamous CellProton TherapyRadiotherapy, Intensity-ModulatedTonsillar NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeProton therapyRadiotherapySurvivalTonsillar cancerToxicity

Identifiers

PMID39198306
PMCPMC11416402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.